



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/060,872	04/15/1998	DAVID A. ESTELL	GC527	1073
	590 04/24/2003			
GENENCOR INTERNATIONAL, INC. ATTENTION: LEGAL DEPARTMENT 925 PAGE MILL ROAD PALO ALTO, CA 94304			EXAMINER	
			SAUNDERS, DAVID A	
TALO ALTO,	CA 94304		ART UNIT	PAPER NUMBER
			1644 DATE MAILED: 04/24/2003	110

Please find below and/or attached an Office communication concerning this application or proceeding.

			7
	Application No.	Applicant(s)	
Advisory Action	09/060,872	ESTELL ET AL.	r
Advisory Action	Examiner	Art Unit	
!	David A Saunders, PhD	1644	
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence addi	'ess
HE REPLY FILED 09 April 2003 FAILS TO PLACE TH herefore, further action by the applicant is required to a nal rejection under 37 CFR 1.113 may only be either: (ondition for allowance; (2) a timely filed Notice of Appexamination (RCE) in compliance with 37 CFR 1.114.	avoid abandonment of this appli 1) a timely filed amendment wh	cation. A proper repich ich places the applic	oly to a cation in
PERIOD FOR RE	EPLY [check either a) or b)]		
a) The period for reply expires 3 months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The datave been filed is the date for purposes of determining the period of exten 7 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened above, if checked. Any reply received by the Office later than three materials are particular term adjustment. See 37 CFR 1.704(b).	visory Action, or (2) the date set forth in the nan SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THate on which the petition under 37 CFR 1, asion and the corresponding amount of the distatutory period for reply originally set in	of the final rejection. IE FINAL REJECTION. S 136(a) and the appropriate e fee. The appropriate extent the final Office action; or	e extension fee ension fee under (2) as set forth in
A Notice of Appeal was filed on Appellant' 37 CFR 1.192(a), or any extension thereof (37 CF	R 1.191(d)), to avoid dismissal	period set forth in of the appeal.	
2.☑ The proposed amendment(s) will not be entered b		, NOTE ! ! \	
(a) they raise new issues that would require furth		(see NOTE below);	
(b) they raise the issue of new matter (see Note)		torially radualna ar a	implifying the
(c) ☐ they are not deemed to place the application issues for appeal; and/or		•	
(d) they present additional claims without cance	ling a corresponding number of	finally rejected clair	ns.
NOTE: See Continuation Sheet.			
B. Applicant's reply has overcome the following reject	tion(s):		
Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted in a	separate, timely filed	d amendment
5.☐ The a)☐ affidavit, b)☐ exhibit, or c)☐ request for application in condition for allowance because: _		sidered but does NC	OT place the
The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLEL	Y to issues which we	re newly
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w			and an
The status of the claim(s) is (or will be) as follows	:		
Claim(s) allowed: 20-23.			
Ciairi(5) allowed. <u>20-23</u> .			
Claim(s) objected to: <u>25</u> .			
Claim(s) objected to: 25.	*		
Claim(s) objected to: <u>25</u> . Claim(s) rejected: <u>14, 17-19, 24, 26-32</u> .	s a)⊡ approved or b)⊡ disar	pproved by the Exan	niner.

9. Note the 10. ☐ Other: _

Continuation of 2. NOTE: Deletion of "one or more cytokines" from claims 17-18 would require further consideration of prior art. Applicant urged addition of cytokines distinguished over prior art (pg 12 of response of 6/4/02).

> David a Saunders DAVID SAUNDERS
> PRIMARY EXAMINER
> ART UNIT 182 /6 //

2